$3.91
0.02[0.51%]
At close: Apr 19
$3.91
0[0.00%]
After Hours: 7:01PM EDT
Novavax
(NASDAQ:NVAX)Novavax Stock (NASDAQ:NVAX), Analyst Ratings, Price Targets, Predictions
Novavax Inc has a consensus price target of $56.5, established from looking at the 20 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and B. Riley Securities on March 1, 2024, August 10, 2023, and August 9, 2023. With an average price target of $23 between HC Wainwright & Co., HC Wainwright & Co., and B. Riley Securities, there's an implied 488.24% upside for Novavax Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
B. Riley Securities
JP Morgan
Cowen & Co.
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Novavax
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/01/2024 | NVAX | Buy Now | Novavax | $3.91 | 385.93% | HC Wainwright & Co. | Vernon Bernardino | $35 → $19 | Maintains | Buy | Get Alert |
| 08/10/2023 | NVAX | Buy Now | Novavax | $3.91 | 795.14% | HC Wainwright & Co. | Vernon Bernardino | → $35 | Reiterates | Buy → Buy | Get Alert |
| 08/09/2023 | NVAX | Buy Now | Novavax | $3.91 | 283.63% | B. Riley Securities | Mayank Mamtani | → $15 | Upgrade | Neutral → Buy | Get Alert |
| 05/10/2023 | NVAX | Buy Now | Novavax | $3.91 | 795.14% | HC Wainwright & Co. | Vernon Bernardino | $110 → $35 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | NVAX | Buy Now | Novavax | $3.91 | 155.75% | B. Riley Securities | Mayank Mamtani | $29 → $10 | Downgrade | Buy → Neutral | Get Alert |
| 02/13/2023 | NVAX | Buy Now | Novavax | $3.91 | 2713.3% | HC Wainwright & Co. | Vernon Bernardino | → $110 | Reiterates | → Buy | Get Alert |
| 01/02/2023 | NVAX | Buy Now | Novavax | $3.91 | 2713.3% | HC Wainwright & Co. | Vernon Bernardino | $207 → $110 | Maintains | Buy | Get Alert |
| 10/14/2022 | NVAX | Buy Now | Novavax | $3.91 | 2022.76% | B. Riley Securities | Mayank Mamtani | $126 → $83 | Maintains | Buy | Get Alert |
| 09/22/2022 | NVAX | Buy Now | Novavax | $3.91 | 590.54% | JP Morgan | Eric Joseph | $132 → $27 | Downgrade | Neutral → Underweight | Get Alert |
| 08/09/2022 | NVAX | Buy Now | Novavax | $3.91 | 2713.3% | Cowen & Co. | Georgi Yordanov | $150 → $110 | Maintains | Outperform | Get Alert |
| 06/08/2022 | NVAX | Buy Now | Novavax | $3.91 | 4196.68% | Cantor Fitzgerald | Charles Duncan | $146 → $168 | Maintains | Overweight | Get Alert |
| 05/20/2022 | NVAX | Buy Now | Novavax | $3.91 | — | B of A Securities | Alec Stranahan | — | Initiates | → Underperform | Get Alert |
| 04/26/2022 | NVAX | Buy Now | Novavax | $3.91 | 5091.82% | B. Riley Securities | Mayank Mamtani | $250 → $203 | Maintains | Buy | Get Alert |
| 03/03/2022 | NVAX | Buy Now | Novavax | $3.91 | 5194.12% | HC Wainwright & Co. | Vernon Bernardino | $294 → $207 | Maintains | Buy | Get Alert |
| 01/21/2022 | NVAX | Buy Now | Novavax | $3.91 | 3736.32% | Cowen & Co. | Georgi Yordanov | → $150 | Initiates | → Outperform | Get Alert |
| 12/21/2021 | NVAX | Buy Now | Novavax | $3.91 | 5245.27% | JP Morgan | Eric Joseph | $172 → $209 | Maintains | Neutral | Get Alert |
| 06/15/2021 | NVAX | Buy Now | Novavax | $3.91 | 6856.52% | Cantor Fitzgerald | Charles Duncan | — | Maintains | Overweight | Get Alert |
| 05/12/2021 | NVAX | Buy Now | Novavax | $3.91 | 5449.87% | Cantor Fitzgerald | Charles Duncan | — | Maintains | Overweight | Get Alert |
| 05/12/2021 | NVAX | Buy Now | Novavax | $3.91 | 7419.18% | HC Wainwright & Co. | Vernon Bernardino | — | Maintains | Buy | Get Alert |
FAQ
What is the target price for Novavax (NVAX)?
The latest price target for Novavax (NASDAQ: NVAX) was reported by HC Wainwright & Co. on March 1, 2024. The analyst firm set a price target for $19.00 expecting NVAX to rise to within 12 months (a possible 385.93% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Novavax (NVAX)?
The latest analyst rating for Novavax (NASDAQ: NVAX) was provided by HC Wainwright & Co., and Novavax maintained their buy rating.
When was the last upgrade for Novavax (NVAX)?
The last upgrade for Novavax Inc happened on August 9, 2023 when B. Riley Securities raised their price target to $15. B. Riley Securities previously had a neutral for Novavax Inc.
When was the last downgrade for Novavax (NVAX)?
The last downgrade for Novavax Inc happened on March 1, 2023 when B. Riley Securities changed their price target from $29 to $10 for Novavax Inc.
When is the next analyst rating going to be posted or updated for Novavax (NVAX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Novavax, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Novavax was filed on March 1, 2024 so you should expect the next rating to be made available sometime around March 1, 2025.
Is the Analyst Rating Novavax (NVAX) correct?
While ratings are subjective and will change, the latest Novavax (NVAX) rating was a maintained with a price target of $35.00 to $19.00. The current price Novavax (NVAX) is trading at is $3.91, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.